Arcus Biosciences, Inc. (RCUS)

Arcus Biosciences Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net Income	-270	-307	-267	53	-123	-84.71
Depreciation & Amortization	10	8	6	4	3	3.58
Loss (Gain) From Sale of Investments	-25	-19	-	5	-	-2.64
Loss (Gain) on Equity Investments	-	-	-	-	-	1.2
Stock-Based Compensation	77	73	65	55	22	8.98
Other Operating Activities	9	10	11	3	1	-
Change in Accounts Receivable	32	15	704	-17	-1	-0.13
Change in Accounts Payable	-	-1	8	-5	9	1.73
Change in Unearned Revenue	-31	-68	-112	-368	188	-2
Change in Other Net Operating Assets	20	-17	23	14	12	0.53
Operating Cash Flow	-158	-306	438	-256	111	-73.46
Capital Expenditures	-11	-24	-6	-26	-3	-1.93
Sale (Purchase) of Intangibles	-	-	-6	-	-	-
Investment in Securities	-96	218	-404	22	-431	61.14
Other Investing Activities	-	-	3	-	-	-
Investing Cash Flow	-107	194	-413	-4	-434	59.21
Issuance of Common Stock	237	33	23	232	439	1.22
Repurchase of Common Stock	-2	-	-	-	-	-0.09
Other Financing Activities	-	-	10	5	-	-
Financing Cash Flow	282	33	33	237	439	1.12
Net Cash Flow	17	-79	58	-23	116	-13.13
Free Cash Flow	-169	-330	432	-282	108	-75.39
Free Cash Flow Margin	-64.26%	-282.05%	385.71%	-73.63%	138.46%	-502.58%
Free Cash Flow Per Share	-1.97	-4.46	6.00	-3.81	1.97	-1.72
Cash Income Tax Paid	5	5	3	-	-	-
Levered Free Cash Flow	-53.5	-187.75	611.75	-644.75	40.73	-41.07
Unlevered Free Cash Flow	-52.25	-186.5	613	-644.75	40.73	-41.07
Change in Net Working Capital	-58	31	-729	711.5	-96.23	-3.74

Source: S&P Capital IQ. Standard template. Financial Sources.